Rauwolscine

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Rauwolscine
Rauwolscine_3D_BS
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 17α-hydroxy-20α-yohimban-16β-carboxylic acid methyl ester
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.004.553 Edit this at Wikidata
Chemical and physical data
FormulaC21H26N2O3
Molar mass354.450 g·mol−1
  • InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15+,17+,18+,19+/m1/s1 checkY
  • Key:BLGXFZZNTVWLAY-DIRVCLHFSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Rauwolscine, also known as isoyohimbine, α-yohimbine, and corynanthidine, is an alkaloid found in various species within the genera Rauvolfia and Corynanthe (including Pausinystalia).[1] It is a stereoisomer of yohimbine.[1] Rauwolscine is a central nervous system stimulant, a local anesthetic and a vague aphrodisiac.[1]

Rauwolscine acts predominantly as a α2-adrenergic receptor antagonist.[2][3] It has also been shown to function as a 5-HT1A receptor partial agonist and 5-HT2A and 5-HT2B receptor antagonist.[4][5][6]

See also

References

  1. ^ a b c Kohli JD, De NN (June 1956). "Pharmacological action of rauwolscine". Nature. 177 (4521): 1182. Bibcode:1956Natur.177.1182K. doi:10.1038/1771182a0. PMID 13334509. S2CID 4212268.
  2. ^ Perry BD, U'Prichard DC (December 1981). "[3H]rauwolscine (alpha-yohimbine): a specific antagonist radioligand for brain alpha 2-adrenergic receptors". European Journal of Pharmacology. 76 (4): 461–464. doi:10.1016/0014-2999(81)90123-0. PMID 6276200.
  3. ^ Qin K, Sethi PR, Lambert NA (August 2008). "Abundance and stability of complexes containing inactive G protein-coupled receptors and G proteins". FASEB Journal. 22 (8): 2920–2927. doi:10.1096/fj.08-105775. PMC 2493464. PMID 18434433.
  4. ^ Arthur JM, Casañas SJ, Raymond JR (June 1993). "Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors". Biochemical Pharmacology. 45 (11): 2337–2341. doi:10.1016/0006-2952(93)90208-E. PMID 8517875.
  5. ^ Kaumann AJ (June 1983). "Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 323 (2): 149–154. doi:10.1007/BF00634263. PMID 6136920. S2CID 23251900.
  6. ^ Wainscott DB, Sasso DA, Kursar JD, Baez M, Lucaites VL, Nelson DL (January 1998). "[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor". Naunyn-Schmiedeberg's Archives of Pharmacology. 357 (1): 17–24. doi:10.1007/PL00005133. PMID 9459568. S2CID 28910390. Archived from the original on 2001-09-11.